In vivo results showed that combination therapy of chemotherapy and anti-PD-1 immunotherapy significantly suppresses the growth of melanoma and prolongs survival time, due to highly selective tumor killing, activation of tumor-specific T cells, and control of the immunosuppressive TME [208]. The gene discussed is PDCD1; the disease is melanoma.